Simranjit Singh

Simranjit Singh is the CEO of Guardant Health AMEA (GH AMEA), a wholly owned subsidiary of Guardant Health, Inc. He has more than 18 years of senior management experience in Asia Pacific working with biopharma, diagnostics, and medical device companies. He leads GH AMEA which is a global leader in precision oncology. GH AMEA’s portfolio of tests which help guide treatment decisions for patients with cancer across the cancer care continuum are available in over 40 different markets across Asia, Middle East & Africa. GH AMEA has two regional offices in Singapore and Tokyo. Prior to Guardant Health, Simranjit was the Vice President of the Medical Devices and Diagnostics Division at IQVIA where he delivered exponential revenue growth by driving business transformation & growing the clinical research, consulting & regulatory business

to advance market share in Asia Pacific.

Please note that speakers provide their own biographies and headshots. Biographies represent the role of the person at the time of their engagement and are not independently verified by the Milken Institute.